

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: TMI59421

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PANTHERYX, INC.		10/02/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Company Name:	STERLING TECHNOLOGY LLC		
Street Address:	1209 Orange Street		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	19801		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	6790196	C COLOSTRUM ONE NATURE'S SUPERFOOD	
Serial Number:	97084332	COLOSTRUMONE EXTRA STRENGTH NATURE'S SUPERFOOD	
CORRESPONDENCE DATA			
Fax Number:	3122367516		
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3123684000		
Email:	ch.tm@dlapiper.com,peggy.mcbride@dlapiper.com		
Correspondent Name:	Michael A Geller Esq.		
Address Line 1:	DLA Piper LLP (US)		
Address Line 2:	P.O. Box 64807		
Address Line 4:	Chicago, ILLINOIS 60606-0089		
ATTORNEY DOCKET NUMBER:	148548-2		
NAME OF SUBMITTER:	Peggy McBride		
SIGNATURE:	Peggy McBride		
DATE SIGNED:	02/28/2024		
Total Attachments: 11			
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page1.tif			
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page2.tif			

CH \$65.00.00 88865015

source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page3.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page4.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page5.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page6.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page7.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page8.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page9.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page10.tif
source=Assignment PANTHERYX, LA BELLE & APR BIOGRAPH to STERLING TECHNOLOGO LLC#page11.tif

ASSIGNMENT OF INTELLECTUAL PROPERTY

This ASSIGNMENT OF INTELLECTUAL PROPERTY (this “Agreement”), dated as of October 2, 2023, is entered into by and among STERLING TECHNOLOGY LLC, a Delaware limited liability company (“Assignee”), and PANTHERYX, INC., a Colorado corporation, PANTHERYX COLOSTRUM HOLDINGS, INC., a Delaware corporation, LA BELLE ASSOCIATES INC., a Washington corporation, APS BIOGROUP, INC., a Colorado corporation, and BLA PROPERTIES LLC, an Arizona limited liability company (each, as “Assignor” and collectively, the “Assignors”). Capitalized terms used but not defined herein shall have their respective meanings as set forth in the Asset Purchase Agreement (as defined below).

BACKGROUND

WHEREAS, each of Assignors and Assignee is party to that certain Asset Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which Assignors have agreed to assign, transfer, convey and deliver to Assignee, and Assignee has agreed to accept from Assignors, all the Acquired Assets (the “Transactions”);

WHEREAS, the Purchase Agreement contemplates execution of this Agreement and this Agreement is subject to the provisions of the Purchase Agreement; and

WHEREAS, Assignors desire to transfer to Assignee, and Assignee desires to receive from Assignors, all of Assignor’s right, title and interest in and to the Acquired Intellectual Property (as defined below), including all intellectual property rights therein and thereto, and all goodwill associated therewith.

NOW THEREFORE, in consideration of the mutual promises provided herein, the Purchase Agreement, and for other good and valuable consideration, the receipt and adequacy of which each party hereby acknowledges, and intending to be legally bound hereby, the parties agree as follows:

AGREEMENT

1. **ASSIGNMENT.** Assignor hereby irrevocably and unconditionally grants, conveys, transfers and assigns to Assignee all of Assignor’s (a) worldwide right, title, and interest in and to (i) all copyrights owned, used or held for use in the operation of the Business, including all common law rights and applications and registrations for the foregoing, (ii) all patent rights owned, used or held for use in the operation of the Business, including, without limitation, the applications and issued patents set forth on Exhibit A, and all future patents that may issue from such patent rights throughout the world, all divisionals, continuations in whole or in part, reexaminations, reissues, substitutions or extensions of any of the foregoing, all foreign counterparts to any of the foregoing, and the right to claim priority to the same, (iii) all trademark, trade name, and service mark rights, in each case owned, used or held for use in the operation of the Business, including all common law rights and applications and registrations for the foregoing, including, without limitation, the applications and registrations set forth on Exhibit A, and the right to claim priority to the same and all renewals thereof, together with the goodwill of the Business symbolized by and associated with the foregoing, (iv) all other intellectual property owned, used or held for use in the operation of the Business, (v) all trade secrets and confidential business information, including confidential ideas, research and development, know-how, methods, formulas, compositions, manufacturing and production processes and techniques, technical and other data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals, (vi) all websites, computer software and firmware (including source code, executable

code, data, databases, user interfaces, algorithms and related documentation) (subsections (i) through (vi) collectively, the “**IP Assets**”) and (vii) all other proprietary or intellectual property rights of any kind or nature throughout the world, in all cases that pertain to or that are embodied by or in any of the IP Assets or are used or held for use in the operation of the Business (collectively, the “**Intellectual Property Rights**”), and (b) worldwide rights to income, royalties, and license fees deriving from the IP Assets and/or Intellectual Property Rights, claims for damages by reason of past, present and future infringement or misappropriation of the IP Assets and/or Intellectual Property Rights or injury to the goodwill associated with the Intellectual Property Rights, and the right to sue for and collect such damages, as permitted under the applicable laws for any jurisdiction or country in which such claims may be asserted for the use and benefit of Assignee and its successors, assigns and other legal representatives, same to be held by Assignee for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignors if this Agreement had not been made.

2. UNASSIGNABLE IP. If any Intellectual Property Rights in or to the IP Assets cannot be assigned as a matter of law (the “**Unassignable IP Rights**”), Assignors hereby grant to Assignee an exclusive (without reservation), irrevocable, perpetual, worldwide, transferable, fully-paid and royalty-free license, with the right to sublicense through multiple tiers, under the Unassignable IP Rights, to (a) reproduce, create derivative works of, distribute, publicly perform, publicly display, and otherwise use the IP Assets and related Intellectual Property Rights in any medium or format, whether now known or hereafter discovered, (b) use, make, have made, sell, offer to sell, import, and otherwise exploit any product, process, or service based on, embodying, incorporating, or derived from the IP Assets and/or the related Intellectual Property Rights, and (c) fully utilize, exploit, and exercise any and all other present or future rights with respect to the IP Assets and the Intellectual Property Rights in any manner without restriction, and Assignors hereby unconditionally and irrevocably waive and quitclaim to Assignee any and all claims and causes of action of any kind against Assignee, its successors, assigns, and other legal representatives, and its licensees (through multiple tiers) with respect to such rights, and agrees, at Assignee’s request and expense, to consent to and join in any action to enforce such rights. Assignors further waive any “moral” rights, or other rights with respect to attribution of authorship or integrity relating to the IP Assets or related Intellectual Property Rights as Assignors may have under any applicable law under any legal theory.

3. ASSISTANCE. From time to time hereafter, and without further consideration, Assignors and its successors and permitted assigns covenant and agree that Assignors and its successors and permitted assigns shall execute and deliver, or shall cause to be executed and delivered, such further instruments of conveyance and transfer and take such additional action as Assignee may reasonably request to effect, consummate, confirm or evidence the transfer to Assignee, its successors and assigns all of the IP Assets and Intellectual Property Rights in accordance with the foregoing, including, without limitation, assistance and cooperation in the registration and enforcement of applicable intellectual property rights or other legal proceedings, including providing documents and materials in the possession or control of Assignors, testifying in any legal proceedings, signing lawful papers and making all lawful oaths, all of the foregoing at Assignors’ expense, and generally doing everything that is reasonable to aid Assignee in obtaining and enforcing proper protection for applicable intellectual property rights and otherwise in the carrying out of the intentions and purposes of this Agreement. If Assignee or its successor or assignee is unable, for any reason, to obtain a signature of an Assignor on a document necessary to perfect the transfer or assignment of the IP Assets or the Intellectual Property Rights, such Assignor hereby irrevocably designates and

appoints Assignee and its duly authorized officers and agents, as such Assignor's agents and attorneys-in-fact to act for and on such Assignor's behalf and instead of such Assignor, solely to execute and file any such document and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by such Assignor.

4. RECORDATION. Assignors authorize the U.S. Commissioner for Patents and the U.S. Commissioner for Trademarks at the U.S. Patent and Trademark Office and any other governmental officials of any patent or trademark office worldwide to record and register this Agreement (or a redacted version thereof) upon request by Assignee.

5. GENERAL.

5.1 Expenses. Except as otherwise provided in Section 3 hereof, Assignors shall pay all costs and expenses incurred by Assignors on its behalf in connection with this Agreement, including fees and expenses of its financial consultants, accountants and counsel. Assignee shall pay all costs and expenses incurred by Assignee or on its behalf in connection with this Agreement, including fees and expenses of its financial consultants, accountants and counsel.

5.2 Exclusive Agreement. This Agreement (including Exhibit A hereto) and the Purchase Agreement constitutes the sole understanding of the parties with respect to the subject matter hereof. In the event of a conflict between a term or condition of this Agreement and a term or condition of the Purchase Agreement with respect to the subject matter hereof, the term or condition of this Agreement shall control.

5.3 Governing Law; Venue; Waiver of Jury Trial. This Agreement, and all claims or causes of action (whether in Contract, tort or statute) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by, and enforced in accordance with, the internal Laws of the State of Delaware, without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdiction other than the State of Delaware. Each of the parties to this Agreement hereby irrevocably and unconditionally submits, for itself and its assets and properties, to the exclusive jurisdiction of the State and Federal Courts sitting in Wilmington, Delaware, and any respective appellate court, in any Action or proceeding arising out of or relating to this Agreement, the agreements delivered in connection with this Agreement, or the transactions contemplated hereby or thereby, or for recognition or enforcement of any judgment relating thereto, and each of the parties to this Agreement hereby irrevocably and unconditionally (a) agrees not to commence any such Action or proceeding except in such courts; (b) agrees that any claim in respect of any such Action or proceeding may be heard and determined in such State courts or, to the extent permitted by Law, in such Federal courts; (c) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such Action or proceeding in any such State or Federal courts; and (d) waives, to the fullest extent permitted by Law, the defense of lack of personal jurisdiction or an inconvenient forum to the maintenance of such Action or proceeding in any such State or Federal courts. Each of the parties to this Agreement hereby agrees that a final judgment in any such Action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each of the parties to this Agreement hereby irrevocably consents to service of process in the manner provided for notices in Section 7.03 of the Purchase Agreement. Nothing in this Agreement shall affect the right of any

party to this Agreement to serve process in any other manner permitted by applicable Legal Requirements.

5.4 Successors and Assigns. This Agreement will be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Agreement may not be assigned or delegated by Assignor without the prior written consent of Assignee, and any attempted assignment by Assignor without such consent shall be null and void. No permitted assignment by Assignor shall relieve Assignor of its obligations hereunder. Assignee may assign its rights or delegate its responsibilities, liabilities and obligations under this Agreement, in whole or in part, without the consent of Assignor.

5.5 Severability. (a) If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions is not affected in any adverse manner to any party and (b) upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner so that the Transactions are fulfilled to the greatest extent possible.

5.6 Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. For the convenience of the parties, any number of counterparts hereof may be executed, each such executed counterpart shall be deemed an original and all such counterparts together shall constitute one and the same instrument. Facsimile transmission (including the e-mail delivery of documents in Adobe PDF format) of any signed original counterpart and/or retransmission of any signed facsimile transmission shall be deemed the same as the delivery of an original.


5.7 Interpretation. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. This Agreement has been drafted and negotiated by all parties, the language set forth herein shall be deemed to be the language of all parties and no rule of strict construction shall be applied against any party. Any drafts of this Agreement prior to the final fully executed draft shall not be used for purposes of interpreting any provision of this Agreement, and each of the parties agrees that no party hereto shall make any claim, assert any defense or otherwise take any position inconsistent with the foregoing in connection with any dispute or Proceeding among any of the foregoing or for any other purpose.

5.8 Amendments. This Agreement may not be amended except by an instrument in writing signed by Assignee and Assignor.

[Remainder of Page Intentionally Blank]

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto.

Assignee:
STERLING TECHNOLOGY, LLC

DocuSigned by:

Sign: _____
Print: Thomas Tench
Title: Secretary

Assignor:
PANTHERYX COLOSTRUM HOLDINGS, INC.

Sign: _____
Print: _____
Title: _____

Assignor:
LA BELLE ASSOCIATES INC.

Sign: _____
Print: _____
Title: _____

Assignor:
APS BIOGROUP, INC.

Sign: _____
Print: _____
Title: _____

Assignor:
BLA PROPERTIES LLC

Sign: _____
Print: _____
Title: _____

Assignor:
PANTHERYX, INC.

Sign: _____
Print: _____
Title: _____

Signature Page to IP Assignment

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto.

Assignee:
STERLING TECHNOLOGY, LLC

Sign: _____
Print: _____
Title: _____

Assignor:
PANTHERYX COLOSTRUM HOLDINGS, INC.

DocuSigned by:
Sign: Wes Parris _____
Wes I 21A78A9B38AB483...
President

Assignor:
LA BELLE ASSOCIATES INC.

DocuSigned by:
Sign: Wes Parris _____
Wes I 21A78A9B38AB483...
President

Assignor:
APS BIOGROUP, INC.

DocuSigned by:
Sign: Wes Parris _____
Wes I 21A78A9B38AB483...
President

Assignor:
BLA PROPERTIES LLC

DocuSigned by:
Sign: Wes Parris _____
Wes I 21A78A9B38AB483...
President

Assignor:
PANTHERYX, INC.

DocuSigned by:
Sign: Wes Parris _____
Wes F 21A78A9B38AB483...
President

Exhibit A

IP Assets

(ii) all patent rights used or held for use in the operation of the Business, including but not limited to:

Country	App. No. / Filing Date	Publication No. / Date	Issue Date	Priority Date	Status	Description
US	17681166 25-Feb-22	20220362303 17-Nov-22		2/26/2021	PUBLISHED	ColostrumOne Extra Strength
WO	PCT/US2022/017937 25-Feb-22	2022183012 01-Sep-22		2/26/2021	PUBLISHED	ColostrumOne Extra Strength

(iii) all trademark, trade name, and service mark rights, in each case owned, used or held for use in the operation of the Business, including but not limited to:

Trademark	Country	Owner	Classes	Reg. No.	Reg. Date	App. No.	App. Date	Status
APS BIOGROUP	Australia	APS BioGroup, Inc.	05 Int.	1967935	13-Nov-2018	1967935	13-Nov-2018	Registered
Miscellaneous Design (Logo)	Australia	APS BioGroup, Inc.	05 Int.	1986115	09-Nov-2018	1986115	09-Nov-2018	Registered
APS BIOGROUP	Brazil	APS BioGroup, Inc.	05 Int.	916342646	17-Sep-2019	916342646	29-Nov-2018	Registered
Infinity Logo	Brazil	APS BioGroup, Inc.	05 Int.	916246116	27-Aug-2019	916246116	12-Nov-2018	Registered
APS BIOGROUP	China (People's Republic)	APS BioGroup, Inc.	05 Int.	34654496	28-Jul-2020	34654496	14-Nov-2018	Registered
APS BIOGROUP	China (People's Republic)	APS BioGroup, Inc.	05 Int.	38317685				Accepted
APS BIOGROUP & Design	China (People's Republic)	APS BioGroup, Inc.	30 Int.	10890601	14-Sep-2013	10890601	09-May-2012	Registered
APS24	China (People's Republic)	APS BioGroup, Inc.	05 Int.	65295697				Pending
APS BIOGROUP24 & Design	China (People's Republic)	APS BioGroup, Inc.	30 Int.	63450698				
APS BIOGROUP24 & Design	China (People's Republic)	APS BioGroup, Inc.	29 Int.	63450694				
APS BIOGROUP	European Union (Community)	APS BioGroup, Inc.	05 Int.	17984407	27-Mar-2019	17984407	13-Nov-2018	Registered

Miscellaneous Design (Logo)	European Union (Community)	APS BioGroup, Inc.	05 Int.	1447187	09-Nov-2018	1447187	09-Nov-2018	Registered
Miscellaneous Design (Logo)	Int'l Registration - Madrid Protocol Only	APS BioGroup, Inc.	05 Int.	1447187	09-Nov-2018	1447187	09-Nov-2018	Registered
IMMULOX	Malaysia	APS BioGroup, Inc.	05 Int.	2017053362	01-Mar-2017	2017053362	01-Mar-2017	Registered
APS BIOGROUP	New Zealand	APS BioGroup, Inc.	05 Int.	1107163	14-May-2019	1107163	13-Nov-2018	Registered
Miscellaneous Design (logo)	New Zealand	APS BioGroup, Inc.	05 Int.	1112743	30-Jul-2019	1112743	09-Nov-2018	Registered
APS BIOGROUP	Taiwan	APS BioGroup, Inc.	05 Int.	2103746	01-Dec-2020	109880268		Registered
APS BIOGROUP	Taiwan	APS BioGroup, Inc.	29 Int.	2069040	01-Jul-2020	109880269		Registered
Miscellaneous Design (logo)	Taiwan	APS BioGroup, Inc.	05 Int.		01-Aug-2019			Registered
APS BIOGROUP	United Kingdom	APS BioGroup, Inc.	05 Int.	UK00917984407	27-Mar-2019	UK00917984407	12-Nov-2018	Registered
Miscellaneous Design (logo)	United Kingdom	APS BioGroup, Inc.	05 Int.	UK00801447187	02-Jul-2019	UK00801447187	08-Nov-2018	Registered
APS BIOGROUP	United States of America	APS BioGroup, Inc.	01 Int.	5219569	06-Jun-2017	86955095	28-Mar-2016	Registered
IMMULOX	United States of America	APS BioGroup, Inc.	05 Int.	4521553	29-Apr-2014	86067795	18-Sep-2013	Registered
IMMUNE BALANCE	United States of America	APS BioGroup, Inc.	05 Int.	3918250	08-Feb-2011	77331061	15-Nov-2007	Suppl. Register
Infinity Logo	United States of America	APS BioGroup, Inc.	05 Int.	5777186	11-Jun-2019	87917760	11-May-2018	Registered
INFOPEPTIDE	United States of America	APS BioGroup, Inc.	05 Int.	3826636	27-Jul-2010	77828618	17-Sep-2009	Suppl. Register
LA BELLE	Brazil	La Belle Associates, Inc	05 Int.	916245691	03-Nov-2021	916245691	12-Nov-2018	Registered

LB (Stylized)	Brazil	La Belle Associates, Inc	05 Int.	916342565	28-Sep-2021	916342565	29-Nov-2018	Registered
FIRST START 100	China (People's Republic)	La Belle Associates, Inc	05 Int.	22849805	21-Feb-2018	22849805	17-Feb-2017	Registered
FIRST START 100 in Chinese Characters	China (People's Republic)	La Belle Associates, Inc	05 Int.	22849804	21-Feb-2018	22849804	17-Feb-2017	Registered
LA BELLE	China (People's Republic)	La Belle Associates, Inc	05 Int.	37001961	15-Oct-2020			Registered
LB (Stylized)	China (People's Republic)	La Belle Associates, Inc	05 Int.	37401414				Pending
LB (Stylized) (in color)	China (People's Republic)	La Belle Associates, Inc	05 Int.	9716983	07-Jan-2013	9716983	14-Jul-2011	Registered
LA BELLE	Int'l Registration - Madrid Protocol Only	La Belle Associates, Inc	05 Int.	1439627	09-Nov-2018	1439627	09-Nov-2018	Registered
LB (Stylized)	Int'l Registration - Madrid Protocol Only	La Belle Associates, Inc	05 Int.	1443951	13-Nov-2018	1443951	13-Nov-2018	Registered
LA BELLE	Japan	La Belle Associates, Inc	05 Int.	1439627	09-Nov-2018	1439627	09-Nov-2018	Registered
LB (Stylized)	Japan	La Belle Associates, Inc	05 Int.	1443951	13-Nov-2018	1443951	13-Nov-2018	Registered
LA BELLE	Mexico	La Belle Associates, Inc	05 Int.	1439627	09-Nov-2018	1439627	09-Nov-2018	Registered
LB (Stylized)	Mexico	La Belle Associates, Inc	05 Int.	1443951	13-Nov-2018	1443951	13-Nov-2018	Registered
AVICOL	United States of America	La Belle Associates, Inc	05 Int.	3489777	19-Aug-2008	77200573	07-Jun-2007	Registered
COLOSTRAL-AID	United States of America	La Belle Associates, Inc	05 Int.	4229874	23-Oct-2012	85572365	17-Mar-2012	Registered
LA BELLE	United States of America	La Belle Associates, Inc	05 Int.	5654074	15-Jan-2019	87915653	10-May-2018	Registered
LB (Stylized)	United States of America	La Belle Associates, Inc	05 Int.	4076155	27-Dec-2011	85183378	23-Nov-2010	Registered

PREMIER SELECT ENRICHED FORMULAS and Design	United States of America	La Belle Associates, Inc	05 Int.	3528091	04- Nov- 2008	77063724	13- Dec- 2006	Registered
C ColostrumOne Nature's Superfood & Design	China (People's Republic)	PanTheryx, Inc.	01 Int.	62443644				Pending
C ColostrumOne Nature's Superfood & Design	China (People's Republic)	PanTheryx, Inc.	05 Int.	62455939				Pending
EXTRA STRENGTH ColostrumOne Nature's Superfood & Design	China (People's Republic)	PanTheryx, Inc.	01 Int.	1667766	18- May- 2022	1667766	18- May- 2022	Registered
EXTRA STRENGTH ColostrumOne Nature's Superfood & Design	China (People's Republic)	PanTheryx, Inc.	05 Int.	1667766	18- May- 2022	1667766	18- May- 2022	Registered
EXTRA STRENGTH ColostrumOne Nature's Superfood & Design	China (People's Republic)	PanTheryx, Inc.	01 Int., 05 Int.	1667766	18- May- 2022	1667766	18- May- 2022	Registered
C ColostrumOne & Design (in Color-Gold & Black)	European Union (Community)	PanTheryx, Inc.	01 Int., 05 Int.	18508473	09- Nov- 2021	18508473	05- Jul- 2021	Registered
EXTRA STRENGTH ColostrumOne Nature's Superfood & Design	Int'l Registration - Madrid Protocol Only	PanTheryx, Inc.	01 Int., 05 Int.	1667766	18- May- 2022	1667766	18- May- 2022	Registered
C ColostrumOne Nature's Superfood & Design (in color)	Taiwan	PanTheryx, Inc.	01 Int., 05 Int.			112031378	11- May- 2023	Pending
C ColostrumOne & Design (in Color-Gold &	United Kingdom	PanTheryx, Inc.	01 Int., 05 Int.	UK00003664515	12- Nov- 2021	UK00003664515	05- Jul- 2021	Registered

Black)								
C ColostrumOne Nature's Superfood & Design	United States of America	PanTheryx, Inc.	01 Int., 05 Int.	6790196	12- Jul- 2022	88865015	08- Apr- 2020	Registered
EXTRA STRENGTH ColostrumOne Nature's Superfood & Design	United States of America	PanTheryx, Inc.	01 Int., 05 Int.			97084332	20- Oct- 2021	Allowed

(iv) all other intellectual property owned, used or held for use in the operation of the Business, including but not limited to:

A. Exclusive Intellectual Property Licenses: None.

B. Domain Names:

<https://apslabelle.com/>

<https://labelleinc.com>

<https://apsbiogroup.com/>

C. Intellectual Property Licenses: None.